South Africa is one of the first countries involved in the AU-3S programme during the pilot phase, notably as it represents the largest clinical trial base in Africa. The AU-3S team engages primarily with representatives from the South African Health Products Regulatory Authority (SAHPRA), working with Dr Boitumelo Semete (CEO) and her team, as well as individuals from the national EPI. Here’s a glimpse into what select individuals from South Africa have had to say about the AU-3S programme:

“We have limited capacity to analyse data we collect, so having access to AU-3S signal detection is a major benefit” – Mafora Matlala, Head of PV Unit for SAHPRA

“Pooling data from different countries once a vaccine has been rolled out to a large population is best for signal detection” – Prof. Hannelie Meyer, Head of The South African Vaccination, and Immunisation Centre at Sefako Makgatho Health Sciences University